NCT07178431View on ClinicalTrials.gov

MB-CART2019.1 in Refractory Multiple Sclerosis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

February 28, 2030

Study Completion Date

December 30, 2030

Conditions
Multiple SclerosisCAR T Cell Therapy
Interventions
BIOLOGICAL

MB-CART2019.1

CAR T cell therapy

Trial Locations (1)

13353

Charité Universitätsmedizin Berlin, Berlin

Sponsors
All Listed Sponsors
lead

Miltenyi Biomedicine GmbH

INDUSTRY